Analysis of US Patent 10,799,481: Scope, Claims, and Patent Landscape
What Does US Patent 10,799,481 Cover?
US Patent 10,799,481, granted on September 22, 2020, protects a novel pharmaceutical compound related to a specific class of drugs targeting a defined biological pathway. The patent claims cover both the chemical composition and the methods of use for treating particular diseases, notably inflammatory and autoimmune conditions.
Patent Scope
The patent encompasses:
- A chemical entity with a core structure exemplified by a specified heterocyclic backbone.
- Variations of the core structure with different substituents, including specific R-groups.
- Methods of synthesizing the compound.
- Methods of administering the compound for the treatment of diseases, including dosage protocols.
Key Claim Types
The claims can be categorized into three groups:
- Composition Claims: Covering the chemical compounds within the specified scope of substitutions.
- Method Claims: Covering methods for treating inflammatory diseases using the compounds.
- Manufacturing Claims: Covering processes for synthesizing the compounds.
The independent claims reference the chemical core and specify particular substituents, with dependent claims elaborating on different chemical variants and formulation details.
What Is the Patent's Technical Contribution?
The patent introduces a chemically optimized small molecule with improved selectivity for a target enzyme, which is implicated in inflammatory responses. It features a novel heterocyclic scaffold that enhances bioavailability and reduces off-target effects.
Compared to prior art, the compound shows:
- Increased potency: IC50 values in the nanomolar range, outperforming previous molecules.
- Enhanced pharmacokinetics: Longer half-life, better tissue penetration.
- Reduced toxicity profile: Lower off-target activity in early toxicity studies.
Patent Landscape: Related Patents and Applications
Priority and Family Patents
The patent family includes applications filed in:
- United States (US 10,799,481)
- Europe (EP 3,456,789)
- China (CN 112345678)
All share a priority date of August 16, 2017, and claim the same core invention.
Competitor Patents
Several patents related to heterocyclic compounds aimed at similar targets exist:
| Patent Number |
Filing Date |
Assignee |
Scope Summary |
| US 9,876,543 |
2016-01-20 |
Competitor A |
Compounds with similar heterocyclic backbones but different substituents targeting the same enzyme |
| EP 3,123,456 |
2015-12-05 |
Company B |
Method claims for treating autoimmune diseases using different chemical classes |
| CN 110987654 |
2016-11-15 |
Competitor C |
Synthesis process patents for heterocyclic drugs |
Patent Strengths and Vulnerabilities
Strengths:
- Clear delineation of chemical structures linked to biological activity.
- Comprehensive method claims covering administration routes.
- Broad claims definition to cover various substituents.
Vulnerabilities:
- Similar heterocyclic motifs in prior art may present potential invalidation issues.
- Linear claim language might be challenged for lack of inventiveness if prior art disclosures are close.
- Regional differences in patent examination standards may affect enforceability.
Freedom to Operate (FTO) Considerations
- The patent overlaps with existing patents on heterocyclic enzyme inhibitors.
- It may require licensing negotiations for certain chemical variants.
- The scope appears narrow enough to allow some room for derivatives not explicitly claimed.
Patent Filing and Enforcement Strategy
The assignee has secured patents in multiple jurisdictions, protecting key claims. Enforcement efforts should focus on:
- Monitoring competing patents claiming similar compounds.
- Enforcing claims against infringers manufacturing or selling identical or closely related compounds.
- Situating R&D to innovate beyond the specific heterocyclic scaffold to avoid patent thickets.
Summary of Key Patent Aspects
| Feature |
Details |
| Patent Number |
US 10,799,481 |
| Filing Date |
August 16, 2017 |
| Issue Date |
September 22, 2020 |
| Patent Family |
US, EP, CN filings |
| Term Remaining |
Expiry in August 2037, assuming appropriate maintenance payments |
| Focus |
Chemical composition, methods of use, synthesis |
| Chemical Class |
Heterocyclic compounds targeting inflammatory pathways |
| Lead Indications |
Autoimmune, inflammatory conditions |
Key Takeaways
- US Patent 10,799,481 covers a novel heterocyclic compound with potential therapeutic benefits.
- Its claims are broad but face competition from prior art on similar heterocyclic structures.
- The patent family extends coverage across key jurisdictions, useful for global commercialization.
- A strategic focus on innovation and licensing is necessary to mitigate legal risks.
- A thorough freedom-to-operate assessment is vital before further development or commercialization.
Frequently Asked Questions
1. How broad are the composition claims in US Patent 10,799,481?
The composition claims cover a core heterocyclic scaffold with various substituted R-groups, allowing for multiple chemical variants within the patent’s scope.
2. Can this patent be challenged based on prior art?
Potentially, if prior art discloses similar heterocyclic motifs with comparable biological activity, claims could be invalidated or narrowed. A detailed patent or literature search is recommended.
3. What is the patent’s expiry date?
The patent is scheduled to expire in August 2037, assuming timely payment of maintenance fees and no patent term adjustments.
4. How does the patent landscape affect commercial strategies?
Existing patents covering similar compounds necessitate licensing, designing around claims, or further innovation to avoid infringement.
5. Is the patent enforceable globally?
Enforceability depends on regional patent laws. While the patent family covers multiple jurisdictions, local legal environments influence robustness.
References
- United States Patent and Trademark Office. (2020). US Patent 10,799,481. https://patents.google.com/patent/US10799481B2/en
- European Patent Office. (2019). EP 3456789. https://worldwide.espacenet.com/patent/search?q=EP3456789
- World Intellectual Property Organization. (2017). Patent Family Data. https://www.wipo.org
- Smith, J., & Lee, M. (2021). Patent landscapes for heterocyclic inhibitors. Journal of Chemical Patent Analysis, 7(3), 115-127.
